4.8 Article

The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer

Journal

NUCLEIC ACIDS RESEARCH
Volume 44, Issue 3, Pages 1227-1246

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/nar/gkv1515

Keywords

-

Funding

  1. Wellcome Trust-GSK Imperial College Clinical Fellowship [PS1903]
  2. Wellbeing of Women [RG1319]
  3. Ovarian Cancer Action
  4. Cancer Research UK
  5. Department of Health [C37/A7283, C2195/A15579]
  6. Imperial Cancer Research UK Centre [C42671/A12196]
  7. Wellcome Trust
  8. MRC [MR/J007986/1] Funding Source: UKRI
  9. Cancer Research UK [22598, 10337, 12011, 16584] Funding Source: researchfish
  10. Medical Research Council [MR/J007986/1] Funding Source: researchfish
  11. National Institute for Health Research [NIHR/CS/009/009] Funding Source: researchfish
  12. Ovarian Cancer Action [OCA10] Funding Source: researchfish
  13. Wellbeing of Women [RG1319] Funding Source: researchfish

Ask authors/readers for more resources

RNA-binding proteins (RBPs) are increasingly identified as post-transcriptional drivers of cancer progression. The RBP LARP1 is an mRNA stability regulator, and elevated expression of the protein in hepatocellular and lung cancers is correlated with adverse prognosis. LARP1 associates with an mRNA inter-actome that is enriched for oncogenic transcripts. Here we explore the role of LARP1 in epithelial ovarian cancer, a disease characterized by the rapid acquisition of resistance to chemotherapy through the induction of pro-survival signalling. We show, using ovarian cell lines and xenografts, that LARP1 is required for cancer cell survival and chemotherapy resistance. LARP1 promotes tumour formation in vivo and maintains cancer stem cell-like populations. Using transcriptomic analysis following LARP1 knockdown, cross-referenced against the LARP1 interactome, we identify BCL2 and BIK as LARP1 mRNA targets. We demonstrate that, through an interaction with the 3' untranslated regions (3'UTRs) of BCL2 and BIK, LARP1 stabilizes BCL2 but destabilizes BIK with the net effect of resisting apoptosis. Together, our data indicate that by differentially regulating the stability of a selection of mRNAs, LARP1 promotes ovarian cancer progression and chemotherapy resistance.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available